Sensex:
83,432.89
(0.01%)
Nifty:
25,461.30
(0.00%)
GO
anubhai
angaldas Securities Pvt. Ltd.
Member: BSE - NSE - CDSL
Technology
.
Transparency
.
Trust
Back Office
Contact Us
Apply For IPO
×
Home
About Us
Market
Contact
Trade Now
Products & Services
Report
Fund Transfer
Closure Account Steps
Home
About Us
Market
Trade Now
Products & Services
Report
Fund Transfer
Closure Account Steps
MARKET
Equity
Derivatives
Mutual Funds
IPO
Other Markets
Equity
Derivative
Mutual Funds
IPO
Other Markets
IPO
Forthcoming Issues
Open Issues
Closed Issues
New Listings
Basis of Allotment
Draft Prospectus
New Issue Monitor
Best Performers
IPO Synopsis
Alivus Life Sciences Ltd
Registered Office: Plot No. 170-172 Chandramouli, Industrial Est.Mohol Bazarpeth, Solapur - 413213, Maharashtra
Phone: 1
Email:
1
Website:
1
Initial public offer of 21,022,222 equity shares of face value of Rs. 2 each ("equity shares") of Glenmark Life Sciences Limited ("Company" or "Issuer") for cash at a price of Rs. 720 per equity share (including a share premium of Rs. 718 per equity share) aggregating to Rs. 1513.60 crores (the "offer") comprising a fresh issue of 14,722,222 equity shares aggregating to Rs. 1060 crores (the "fresh issue") and an offer for sale of up to 6,300,000 equity shares by Glenmark Pharmaceuticals Limited ("Promoter Selling Shareholder") and such equity shares, The "offered shares") aggregating to Rs. 453.60 crores (The "offer for sale"). The offer shall constitute 17.16% of the post-offer paid-up equity share capital of the company. The face value of equity shares is Rs. 2 each. Offer Price : Rs. 720 per Equity Share of face value of Rs. 2 each. Anchor Investor offer price: Rs. 720 per Equity share. The Offer Price is 360 times the face value.
Issue
Money Payable On
Opens On
Closes On
Application
Allotment
27-Jul-2021
29-Jul-2021
720.00 - 0.00
0.00 - 0.00
Cr.
Lead Managers to the Issue
Project Cost
1,060.00
Project Financed through Current Offer
1,513.60
Post Issue Equity Share Capital
24.51
Issue Price
720.00
Projects
Payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company pursuant to the Business Purchase agreement
Funding capital expenditure requirements
General corporate purposes
Promoted By
Glenmark Pharmaceuticals Ltd
BSE
NSE
Registrar to the Issue
Attention Investor
As per CDSL communiqué Kindly update your Email ID, Mobile Number & Income Range in CDSL demat Account on or before 31st May 2021, Non Compliance Account will be INACTIVE after 31st May 2021. | Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for
all debit and other important transactions
in your demat account directly from CDSL on the same day......................
issued in the interest of investors.
| "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account." | "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of Investors.